Altering microtubule dynamics is synergistically toxic with spindle assembly checkpoint inhibition by Schukken, Klaske M et al.
  
 University of Groningen
Altering microtubule dynamics is synergistically toxic with spindle assembly checkpoint
inhibition
Schukken, Klaske M; Lin, Yu-Chih; Bakker, Petra L; Schubert, Michael; Preuss, Stephanie F;






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Schukken, K. M., Lin, Y-C., Bakker, P. L., Schubert, M., Preuss, S. F., Simon, J. E., ... Foijer, F. (2020).
Altering microtubule dynamics is synergistically toxic with spindle assembly checkpoint inhibition. Life
science alliance, 3(2). https://doi.org/10.26508/lsa.201900499
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 19-05-2020
Research Article
Altering microtubule dynamics is synergistically toxic with
spindle assembly checkpoint inhibition
Klaske M Schukken1, Yu-Chih Lin2,*, Petra L Bakker1,*, Michael Schubert1 , Stephanie F Preuss1 , Judith E Simon1,
Hilda van den Bos1 , Zuzana Storchova3 , Maria Colome´-Tatche´1,4,5, Holger Bastians2 , Diana CJ Spierings1 ,
Floris Foijer1
Chromosomal instability (CIN) and aneuploidy are hallmarks of
cancer. As most cancers are aneuploid, targeting aneuploidy or
CIN may be an effective way to target a broad spectrum of
cancers. Here, we perform two small molecule compound screens
to identify drugs that selectively target cells that are aneuploid or
exhibit a CIN phenotype. We find that aneuploid cells are much
more sensitive to the energy metabolism regulating drug ZLN005
than their euploid counterparts. Furthermore, cells with an on-
going CIN phenotype, induced by spindle assembly checkpoint
(SAC) alleviation, are significantly more sensitive to the Src kinase
inhibitor SKI606. We show that inhibiting Src kinase increases
microtubule polymerization rates and, more generally, that dereg-
ulating microtubule polymerization rates is particularly toxic to cells
with adefective SAC. Ourfindings, therefore, suggest that tumorswith
a dysfunctional SAC are particularly sensitive to microtubule poisons
and, vice versa, that compounds alleviating the SAC provide a
powerful means to treat tumors with deregulated microtubule
dynamics.
DOI 10.26508/lsa.201900499 | Received 24 July 2019 | Revised 7 January
2020 | Accepted 8 January 2020 | Published online 24 January 2020
Introduction
Chromosomal INstability (CIN) is the process through which
chromosomes mis-segregate during mitosis. CIN leads to cells with
an abnormal DNA content, a state known as aneuploidy. As three of
four cancers are aneuploid (Weaver & Cleveland, 2006; Foijer et al,
2008; Duijf et al, 2013), CIN is considered an important contributor to
tumorigenesis. Indeed, CIN has been associated with metastasis
(Bloomfield & Duesberg, 2016; Xu et al, 2016), increased probability
of drug resistance (Lee et al, 2011; Sansregret & Swanton, 2017) and
generally, a lowered patient survival (Carter et al, 2006; Walther
et al, 2008; McGranahan et al, 2012). While the frequent occurrence
of CIN and resulting aneuploidy in cancer is generally attributed to
the acquired ability of cancer cells to adapt their palette of on-
cogenic features as the tumor evolves, ongoing chromosome mis-
segregation also has negative effects on cancer cells. The downside of
CIN for cancer cells is that most newly acquired karyotypes lead to
reduced proliferation (Torres et al, 2007; Williams et al, 2008; Foijer
et al, 2017) and induction of aneuploidy-imposed stresses (Torres et al,
2010). In addition to this, ongoing missegregation causes further
structural DNA damage (Zhang et al, 2015; MacKenzie et al, 2017) that,
together with unfavorable karyotypes, leads to cell death (Kops et al,
2004; Burds et al, 2005; Santaguida et al, 2017) or senescence (Andriani
et al, 2016).
To protect from CIN, cells have mechanisms in place that
maintain proper chromosome inheritance. The Spindle Assembly
Checkpoint (SAC) is one such mechanism preventing CIN by
inhibiting the onset of anaphase until all chromosomes are
properly attached to the two opposing spindle poles, reviewed in
detail by Musacchio and Salmon (2007). Interfering with the SAC,
for instance, by inactivating key components of the checkpoint
leads to frequent chromosome mis-segregation events and is
commonly used to study the consequences of CIN in vitro and in
vivo (Kops et al, 2004; Foijer et al, 2013, 2014, 2017).
Although SAC impairment is rare in human cancer (Gordon et al,
2012), many cancers show signs of a partially impaired SAC, for
instance, as a result of increased expression of proteins with a
direct role in the SAC or their regulators, such as Rb mutations that
lead to increased expression of Mad2, and thus, provoke a CIN
phenotype (Pfau & Amon, 2012). Furthermore, altered microtubule
(MT) dynamics are another source of CIN in many cancers (Bakhoum
et al, 2009; Ertych et al, 2014; Stolz et al, 2015) as restoring tubulin
dynamics to normal levels can decrease CIN rates in many cancer cell
lines (Ertych et al, 2014). Conversely, commonly used cancer drugs
such as paclitaxel or vincristine interfere withMT polymerization rates,
thus increasing CIN rates in cancer cells. This observation suggests
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that imposing CIN phenotypes onto cancer cells is a powerful strategy
to eradicate tumors. However, it is not yet clear whether exacerbating
CIN in cells with a preexisting CIN phenotype is wise or not.
As CIN and aneuploidy discriminate cancer cells from healthy
cells, both make for attractive targets for cancer therapy. To reveal
potential general vulnerabilities of aneuploid cells, Tang et al (2011)
performed a small molecule compound screen, which revealed the
energy stress-inducing compound 5-Aminoimidazole-4-carboxamide
ribonucleotide (AICAR) to be more toxic to aneuploid cells than eu-
ploid cells (Tang et al, 2011). This aneuploidy-specific toxicity was
shown to be true in cell culture experiments as well as in cancer
mouse models, a promising result for future aneuploid cancer
therapies.
Although CIN and aneuploidy are intimately related, CIN has
additional effects on cell physiology and growth in addition to
those imposed by the resulting aneuploidy (Schukken and Foijer,
2018). Because CIN drives karyotype heterogeneity, thus increasing
the rate of evolution that cancer cells use to acquire new features
and adapt (McGranahan et al, 2012; Giam & Rancati, 2015), targeting
CIN would provide an evenmore powerful means to kill cancer cells
than aneuploidy alone.
In this study, we, therefore, performed two small-scale drug
screens, one to identify small molecule compounds that target
aneuploid cells and another to find compounds that are more toxic
to CIN cells than to chromosomally stable cells. For this purpose, we
selected a collection of drug-like molecules from a list of drugs
already being used in the clinic or in advanced-stage clinical trials.
Compounds were further selected for their potential role in tar-
geting CIN or aneuploid cells, such as targeting cell survival
(Dekanty et al, 2012; Foijer et al, 2013), proliferation (Williams et al,
2008; Ben-david et al, 2014; Gogendeau et al, 2015; Sheltzer et al,
2017), protein processing (Oromendia et al, 2012; Stingele et al, 2012),
DNA repair (Bakhoum et al, 2014, 2018), transcriptional deregulation
(Upender et al, 2004; Stingele et al, 2012), and cellular metabolism
(Williams et al, 2008; Tang et al, 2011) as these processes are
typically deregulated in aneuploid cells. Indeed, our screen for
aneuploidy-targeting compounds revealed a compound targeting
cellular metabolism, validating earlier findings from the Amon
laboratory (Tang et al, 2011). Furthermore, the CIN screen revealed
that the Src inhibitor SKI606 (bosutinib) is synergistically toxic to
cells with an alleviated SAC. We find that themechanism underlying
the toxicity of SKI606 in SAC-deficient cells results from deregulated
tubulin polymerization rates imposed by Src inhibition. Our results,
therefore, indicate that combining SAC inhibition with tubulin
deregulation is synergistically toxic to cells and might provide a
powerful means to target cancer cells with a CIN phenotype.
Results
CIN and the resulting aneuploidy lead to a deregulated tran-
scriptome and proteome (Tang et al, 2011; Stingele et al, 2012; Foijer
et al, 2013, 2014) and can provoke cell cycle delay, senescence, or
apoptosis (Giam & Rancati, 2015; Andriani et al, 2016; Santaguida
et al, 2017; Chunduri & Storchova´, 2019). Furthermore, ongoing
CIN can lead to further DNA damage (Zhang et al, 2015; MacKenzie
et al, 2017). We, therefore, reasoned that targeting RNA or protein
processing, transcriptional regulation, apoptosis, or DNA repair
might be particularly toxic to aneuploid cells and cells exhibiting
a CIN phenotype. As CIN and aneuploidy are different concepts
(Schukken & Foijer, 2018) and have different consequences for cells
(Stingele et al, 2012; Andriani et al, 2016; Schukken & Foijer, 2018)
aneuploidy and CIN might impose different therapeutic vulnera-
bilities. To test this, we performed two small-scale drug screens,
one to identify compounds that selectively prevent the propa-
gation of aneuploid cells and another to identify small molecules
that selectively targets CIN cells.
A small-scale drug screen to identify compounds that selectively
target aneuploid cells
We first selected 95 drug-like molecules from a drug library com-
posed of drugs that target processes that aneuploid or CIN cells
might rely on and are already being used in the clinic or being tested
in clinical trials (Table S1). Next, we determined the initial drug
concentration for each drug to be used in the screen. For this, we
exposed wild-type RPE1 cells (a near-diploid non-cancer cell line
derived from retinal epithelium [Soto et al, 2017]) to decreasing
concentrations of the drugs, starting at 10 μM for all compounds, and
compared cell proliferation of drug-exposed cells to proliferation of
DMSO-treated cells over a period of 7 d. We purposely chose an
untransformed cell line, as this allows studying the combinational
effect of CIN and drugs in an otherwise unperturbed setting.
Next, we subjected stable aneuploid RPE-1 cells, trisomic for
chromosomes (chrs.) 5 and 12 (Fig S1A, [Stingele et al, 2012]), to the
same drug-treatment regime and compared proliferation between
diploid and aneuploid RPE1 cells (Supplemental Data 1) using an
IncuCyte high content imager. Fig S1B schematically shows the
experimental design and analysis approach. Note that aneuploid
RPE1 cells showed a modestly reduced proliferation rate compared
with control RPE1 cells (Fig S1C) in line with earlier observations
(Williams et al, 2008) for which we corrected when analyzing the
growth curves. To quantify differences between wild-type and
aneuploid RPE1 cells, we compared the area under the curve (AUC)
as a measure of cumulative cell growth (Fig 1A and B) and the slope
of the logarithmic growth as ameasure for the proliferation rate (Fig
1C and D), also see the Materials and Methods section. While this
screen revealed some drugs for which aneuploid RPE1 cells were
more sensitive (log2 > 0; P < 0.05) or less sensitive (log2 < 0; P < 0.05),
we only found one compound (#2379, ZLN005; a transcriptional
regulator of PGC-1α) for which the effect was significant after
Bonferroni multiple testing correction (Fig 1A) in one of the two
screens. The combined effects of aneuploidy and ZLN005 act
synergistically as assessed by a Bliss independence test (50%
stronger effect than additive, P = 3.2E-3, [Zhao et al, 2014]). Indeed,
further validation confirmed the selective growth defect of aneu-
ploid RPE1 cells imposed by ZLN005 (Fig 1E). However, as ZLN005
targets energy metabolism, very similar to what others have found
for AICAR (Tang et al, 2011), we did not pursue this compound
further. We, therefore, conclude that our aneuploidy screen did not
uncover novel targetable vulnerabilities of aneuploid cells and next
performed a screen for compounds that selectively inhibits CIN
cells.
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A conditional Mad2 knockdown cell line to model CIN
To screen for compounds that selectively target cells with a CIN
phenotype, we needed a cell line in which CIN can be provoked in
an inducible fashion, as long-term CIN phenotypes are typically
selected against in tissue culture (Kops et al, 2004; Foijer et al, 2014).
For this, we engineered RPE1 hTert cells in which the SAC can be
inhibited through expression of a Doxycycline-inducible Mad2
shRNA construct, from here on referred to as Mad2 conditional
knockdown (Mad2cKD) RPE1 cells. Mad2 knockdown efficiency was
quantified by quantitative PCR (Fig 2A) and Western blot (Fig 2B),
which revealed that Mad2 levels were reduced by 90% within 3 d of
doxycycline treatment. To test whether Mad2 inhibition was suf-
ficient to alleviate the SAC, we exposed cells to the MT poison
nocodazole, determined accumulation in mitosis by quantifying
phospho-histone H3 using flow cytometry, and found that dox-
treatment for 3 d or longer was sufficient to completely alleviate the
SAC in Mad2cKD RPE1 cells (Fig 2C). Therefore, for all follow-up
experiments involving Mad2cKD RPE1 cells, the cells were pre-
treated with doxycycline for a minimum of 3 d before drug ad-
ministration. As expected, we found that Mad2cKD moderately
decreased cell proliferation (~25%), which we corrected for in our
downstream analyses in each of our experiments (Fig S2A). Next, we
determined whether SAC inhibition in Mad2cKD RPE1 cells indeed
leads to a CIN phenotype. To this aim, we quantified interphase and
mitotic abnormalities using live cell imaging (Fig 2D and E). Indeed,
Mad2cKD cells displayed a significantly increased CIN-rate: 46% of
the Mad2cKD RPE1 cells displayed mitotic abnormalities compared
with only 1% of control cells. In addition, the fraction of cells with
interphase remnants of mitotic aberrations such as micronuclei
increased from 2 to 24%. Finally, we quantified aneuploidy by
single-cell whole genome sequencing (Bakker et al, 2016; van den
Bos et al, 2016). Whereas control RPE1 cells show little aneuploidy (2
of 114 cells sequenced) except for a known structural abnormality
for chromosome 10 (Fig 2F andWorrall et al (2018)), 45% of dox-treated
Mad2cKD cells displayed one to few aneusomies per cell (76 of 169
Figure 1. Aneuploid cells are sensitive to a
metabolism-enhancing drug.
(A, B, C, D) RPE1 control cells and stable aneuploid RPE1
Ts12 Ts5 cells were screened with 95 drugs, each drug
screened in triplicate. 45 drugs were rescreened. The
P-values and the effect size for drug’s effect on RPE1
and RPE1 Ts12 Ts5 cells were plotted. (A, B, C, D) Data
were analyzed through quantification of area under
the curve (AUC, A, B), and slope analysis (C, D) of both
the initial screen (A, C) and rescreened drugs (B, D).
Drugs with difference >1 and P-value < 0.05 after
Bonferroni correction are indicated in blue. (E)
Validation growth curves of RPE1 control and RPE1 Ts12
Ts5 cells with and without 10 μM 2,379. Data were
obtained by sequential daily microscope images and
analyzed by FIJI-PHANTAST. All data involve at least
three biological replicates, each with three technical
replicates. Error bars indicate SEM. P-values are
calculated in two-sided t test for AUC, correcting for cell
line control. DMSO control curves are shared with
Figs S1C and S3G.
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cells, Fig 2G) within 5 d after induction of the Mad2 shRNA, confirming
a substantial CIN phenotype. Together, these features make the
Mad2cKD cells highly suitable to screen for compounds that target
CIN cells.
The Src inhibitor SKI606 selectively targets Mad2cKD cells
We next used the Mad2cKD RPE1 cells to screen for compounds that
selectively inhibit the expansion of CIN cells (Fig S2B). For this, we
exposed control andMad2cKD RPE1 cells to 58 compounds (Table S2)
and compared the maximum proliferation rate and cumulative cell
number between Mad2cKD RPE1 cells and control RPE1 cells using
the same setup as for the aneuploidy screen described above. To
assess both short-term and longer term effects of the drugs, we
quantified proliferation and cumulative cell number over the first
4 d and over days 5–8 separately (Fig S2B). Intriguingly, we found
that the mTor inhibitor AZD8055 (compound #1561) at 0.1 μM acted
synergistically with CIN in reducing cell numbers (31% greater than
additive effect; P = 2.7E-4, Bliss independence test) during the first
4 d of the screen, but became fully toxic to both control andMad2cKD
cells from day 5 onward (Fig 3A and B and Supplemental Data 2 for
all growth curves). Conversely, we found that the Src inhibitor
SKI606 (compound #1407) at 0.1 μM acted synergistically with CIN
(48% greater effect than additive; P = 7.3E-3, Bliss independence
test) during the second half of the screen (Fig 3C and D and
Supplemental Data 2) and less so during the first half of the screen.
Note that the observed effects were not related to the doxycycline
treatment required to induce Mad2 shRNA, as doxycycline alone
had no effect on proliferation (Fig S3A). Next, we wanted to validate
our findings in independent growth assays. In addition to AZD8055
and SKI606, we also retested compounds #2180 (TMP195, HDAC
inhibitor), #2250 (CHR6494 trifluoroacetate, Haspin inhibitor), #2831
(EPZ015666, Prmt5 inhibitor), #1801 (pyroxamide, HDAC 1 inhibitor),
#1803 (MS 275, HDAC 1 and 3 inhibitor), and #2008 (Tenovin 1, SIRT 1 &
2 inhibitor) that also showed some effect in the primary CIN screen.
For these validation experiments, proliferation was quantified by
daily cell confluency measurements from microscope images as
described in the Materials and Methods section. These experi-
ments revealed that although SKI606 (#1407), AZD8055 (#1561),
and EPZ015666 (#2831) reproducibly inhibited the growth of
Mad2cKD RPE1 cells more than that of control cells (Fig 4A–F), this
was not the case for TMP195, CHR6494, pytoxamide, MS 275, and
Tenovin (Fig S3B–G). Given that SKI606 gave the largest growth
inhibitory effect on Mad2cKD RPE1 cells, most notably at 0.5 μM
(Fig 4E), we decided to further pursue this compound. It is in-
teresting to note that SKI606 had no significant effect on stable
aneuploid cells (Fig S3G–J), and vice versa, that ZLN005 (#2379),
identified in the aneuploidy screen, had no significant effect on
Mad2cKD CIN cells (Fig S3K), suggesting that compounds that are
selectively toxic to stable aneuploid cells not necessarily target
CIN cells, and vice versa.
Figure 2. Engineering a cell line for conditional CIN.
(A) Quantitative PCR for Mad2 RNA levels over time in Mad2cKD RPE1 cells. (B) Western blot for Mad2 levels over time in RPE1 in Mad2cKD RPE1 cells. (C) Mitotic
accumulation of nocodazole-challenged control and Mad2cKD RPE1 cells measured by phosphorylated histone H3. (D, E) Quantification of mitotic phenotypes of control
and Mad2cKD RPE1 cells assessed by time-lapse imaging for interphase cells (D) and mitotic cells (E). “n” refers to the number of cells analyzed, P-values from chi-squared
test. Data also displayed in Fig 5H. (F, G) Single-cell whole-genome sequencing data quantified by AneuFinder for RPE1 control cells (F, 114 cells, 2 aneuploid) and
Mad2cKD RPE1 cells after 5 d of doxycycline treatment (G, 169 cells, 76 aneuploid). Colors refer to the copy number state for each chromosome (fragment).
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SKI606 was designed as a tyrosine kinase inhibitor targeting Bcr-
Abl (Golas et al, 2003) and Src (Boschelli et al, 2001). However, RPE1
cells do not have the Bcr-Abl fusion, making Src kinase the likely
target. To test whether the observed effect of SKI606 on prolifer-
ation indeed acts through Src, we next compared the effect of
SKI606 with that of another Src inhibitor, SKI-1. We found that SKI-1
displayed a similar synergy with CIN (Figs 4G and S3L; 15–40% more
effect than additive; Bliss independence test, P-values 1.5E-3 and
1.1E-3 for first 4 and last 4 d, respectively) as SKI606 (Figs 4H and
S3M) in inhibiting proliferation of Mad2cKD RPE1 cells while having
minimal effect on the proliferation of RPE1 control cells. However,
as small molecule compounds can have (overlapping) off-target
effects, we also wanted to confirm the synergy between Src inhi-
bition and an impaired SAC at the genetic level. For this, we
designed three inducible shRNA constructs for Src of which one
(shRNA3) yielded a significant knockdown of Src protein levels in
RPE1 cells (54% knockdown, Fig S3N). Indeed, we found that RPE1
SrccKD cells were muchmore sensitive to the SAC inhibitor reversine
than wild-type RPE1 cells (Fig 4I), particularly during the second half
of the experiment (days 4–7), similar as observed for Mad2cKD cells
treated with SKI606 (compare Fig 4H with 4I). We, therefore, con-
clude that pharmaceutical and genetic inhibition of Src is selec-
tively toxic to cells with an impaired SAC.
The synergy between Mad2 and Src inhibition does not involve
impaired DNA damage signaling
Src is an oncogene, a key regulator of cell survival and mitosis
(Thomas & Brugge, 1997), an activator of DNA-PK (Dittmann et al,
2008), and a regulator of actin organization (Destaing et al, 2008)
and spindle orientation (Nakayama et al, 2012). We, therefore, next
asked what the mechanism is between the observed synergy of SAC
and Src inhibition in preventing cell proliferation. As CIN leads to
DNA damage (Janssen et al, 2011) and Src is involved in activating
the DNA damage response via DNA-PK activation (Dittmann et al,
2008), we next asked whether DNA-PK inhibition would reproduce
the results observed with Src inhibition. For this, we exposed the
cells to a DNA-PK inhibitor at a concentration that significantly
increased γ-H2AX foci after gamma radiation, indicating impaired
DNA repair (Fig S4A). In this case, we found that DNA-PK inhibition
was not synergistically toxic in dox-treated Mad2cKD cells (Fig S4B).
In line with this, another DNA-PK inhibitor that was included in our
screen (compound #1463; NU7441) did not show a differential effect
between control and CIN RPE1 cells. Finally, we found that 4 Gray of
irradiation and SKI606 both decreased proliferation of RPE1 cells as
expected, but that SKI606 did not inhibit the growth of irradiated
cells more than that of controls, indicating that SKI606-invoked
Figure 3. Screen for compounds that selectively kill
CIN cells reveals several candidates.
(A, B, C, D) Growth curves of control and Mad2cKD RPE1
cells were analyzed during the first half (day 1–4) (A, B)
and the second half (day 5–8) of the screen (C, D). (A,
B, C, D) The non-CIN over CIN ratios for AUC (A, C) and
slope analysis (B, D) were plotted per drug against the
P-value. All drugs with log of difference >|0.15|, and
P-value < 0.05 are plotted; drugs with P-values < 0.05
after Bonferroni correction are labeled blue.
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growth inhibition is independent of DNA damage (Fig S4C). We,
therefore, conclude that the observed synergy between Mad2 and
Src inhibition is not caused by exacerbating DNA damage.
SKI606 increases CIN in SAC-deficient cells by deregulating MT
polymerization rates
Because SKI606 does not appear to target aneuploidy-imposed
stresses, nor DNA damage, we next investigated whether SKI606
affects chromosome missegregation rates. For this, we performed
time-lapse imaging experiments with control and Mad2cKD RPE1
cells expressing H2B-GFP and quantified mitotic abnormalities in
the presence or absence of SKI606. Interestingly, we found that
although SKI606 did not increase CIN in control cells, it did sig-
nificantly increase CIN in Mad2cKD cells (Fig 5A), increasing the
missegregation rates from 46 to 79%.
As a parallel approach, we alleviated the SAC using reversine in
RPE1 cells as done for the SrccKD cells (Fig 4I) and found that SKI606
indeed specifically increases chromosome missegregation rates in
reversine-treated cells (Fig 5B). We also found that this phenotype
Figure 4. Validating candidate compounds that selectively target CIN cells.
(A, B, C, D, E, F) Growth curves of control andMad2cKD RPE1 cells treated with 0.1 μM (A) and 0.01 μM (B) compound #1561, (C) 1 μM compound #2831, (D, E, F) 0.1 μM, 0.5 μM, and
1 μM 1,407, respectively. Data were obtained by sequential daily microscope images and analyzed by FIJI-PHANTAST. Each point is aminimum of three biological replicates, each
of which contains three technical replicates. Plotted is log-scaled percentage confluency (cell coverage) over time. Error bars indicate SEM. P-values are calculated from paired,
one-sided t tests of AUC corrected for cell line control. RPE1DMSOandMad2cKD DMSO curves shared between (A) and (B), andbetween (C) and (F) and Fig S3C, andbetween (D)
and (E). (G, H) IncuCyte growth curves of control andMad2cKDRPE1 cells treatedwith Src inhibitors SKI-1 (G) or compound #1407 (H, SKI606) for day 8–16. (I) IncuCyte growth curves
for control- and reversine-treated RPE1 cells with andwithout conditional Src knockdown. All points include data for six technical replicates. Error bars refer to SEM, and P-values
were calculated from two-sided t test of the AUC corrected for cell line controls. Data for DMSO control curves are shared between (G, H) and Fig 5G.
Src inhibitors cause CIN specifically in SAC-inhibited cells Schukken et al. https://doi.org/10.26508/lsa.201900499 vol 3 | no 2 | e201900499 6 of 15
Figure 5. 1,407 significantly increases CIN in spindle assembly checkpoint (SAC)–deficient cells by altering microtubule (MT) dynamics.
(A, B, C) Frequency of mitotic abnormalities in control and Mad2cKD RPE1 cells with and without 0.5 μM compound #1407 (A), RPE1 cells with 150 nM reversine with and
without 0.5 μMcompound #1407 (B), andMCF7 cells treated with 15 nM reversine and/or 0.5 μMcompound #1407 (C). Data were obtained by time-lapsemicroscopy imaging
and include at least three biological replicates. P-values are calculated from chi-squared test. (D) Quantification of time from start prophase to late metaphase for control
and Mad2cKD RPE1 cells with and without 0.5 μM compound #1407. At least 29 mitoses were analyzed per condition from a minimum of three time-lapse microscopy
experiments. (E) Boxplot showing mean cell migration speed (μm/second) of RPE1 cells with or without 0.5 μM 1,407. Data include a minimum of three independent
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persisted in other cell lines. For instance, SKI606 increased CIN
rates of reversine-treated MCF7 breast cancer cells from 30 to 46%,
whereas SKI606 did not change CIN rates of MCF7 cells (17–19%) in
the absence of reversine (Fig 5C). Together, these observations
suggest that Src inhibition exacerbates a CIN phenotype specifically
in cells with an impaired SAC.
To further investigate the mechanism underlying the effects of
SKI606 on chromosome segregation, we determined whether Src
inhibition had an effect onmitotic timing. For this, we compared the
mitotic length between control and Mad2cKD RPE1 cells, with and
without Src inhibition. Although Mad2 alleviation decreased the
time from prophase to metaphase as observed previously (Meraldi
et al, 2004), mitotic length again increased when Mad2cKD RPE1 cells
were exposed to SKI606 (Fig 5D). This suggests that the increased
chromosome missegregation rates in SKI606-treated Mad2cKD cells
were not caused by further SAC inhibition andmight, therefore, be the
result of altered MT dynamics. Mitotic timing of control RPE1 cells was
unaffected by SKI606 treatment in line with the absence of a CIN
phenotype in SKI606-treated control RPE1 cells. Furthermore, when
analyzing the time-lapse data, we also noted that SKI606-treated cells
(RPE1 [Fig 5E] and MCF7 cells [Fig S5A]) displayed reduced cell motility,
also suggesting an effect of SKI606 on MT dynamics.
Given our results and a known role for Src in spindle orientation
(Nakayama et al, 2012) and MT nucleation (Colello et al, 2010), we
next investigated the effect of SKI606 on MT dynamics in a number
of CIN and non-CIN (cancer) cell lines. For this, we quantified MT
dynamics by time-lapse imaging in control- and SKI606-treated
cells expressing EB3-GFP, which labels the plus-end tips of MTs and
can, therefore, be used to quantify MT dynamics (Stepanova et al,
2003). Taking this approach, we found that SKI606 significantly
increased MT polymerization rates in RPE1 as well as in diploid,
non-CIN HCT116 cancer cells. Interestingly, we found that SKI606
increased the MT polymerization rates in these non-CIN cell lines to
rates comparable with those observed in the CIN cancer cell lines
SW620 and HT29 (Fig 5F and Videos 1–8). However, SKI606 treatment
failed to further increase MT polymerization rates in HT29 cells, and
only had a minor effect on MT polymerization rates in SW620 cells,
suggesting that MT polymerization rates had reached their physi-
ological maximum in these lines (Fig 5F and Videos 1–8). Similar as
observed for RPE1 and MCF7 cells, we found that SKI606 treatment
did not increase chromosome missegregation rates in DMSO-
treated HT29 cells (Fig S5B). However, whereas reversine treat-
ment modestly increased CIN rates in HT29 cells as expected,
combined SKI606 and reversine treatment failed to increase CIN
rates in HT29 cells further (Fig S5B), providing additional proof that
SKI606 acts through deregulating MT polymerization rates. Given
these results, and as increased MT polymerization rates have previ-
ously been shown to drive CIN phenotypes (Ertych et al, 2014), we
conclude that SKI606 contributes to a CIN phenotype by altering MT
polymerization rates.
Altering MT dynamics is synergistically toxic with SAC inhibition
To determine whether the synergy between altering MT dynamics
and SAC inhibition was specific to SKI606 or would also apply to
other MT poisons, we next tested the effect of SAC alleviation with
low doses of nocodazole that do not trigger the SAC but only cause
increased MT polymerization rates (Ertych et al, 2014). For this, we
first determined a nontoxic concentration for long-term (up to 8 d)
treatment of nocodazole. Whereas 250, 100, 50, and 25 ng/ml of
nocodazole completely inhibited proliferation under these con-
ditions, 10 ng/ml (33 nM) nocodazole was compatible with cell
division. Indeed, although 33 nM nocodazole still reduced prolif-
eration of RPE1 control cells, it was significantly more toxic to
Mad2cKD RPE1 cells, confirming the synthetic lethality between SAC
inhibition and deregulating MT polymerization rates (Figs 5G and
S5C, 13% more than additive effect, P = 7.0E-3, Bliss independence
test). Also in this setting, the observed synergy between low doses
of nocodazole and SAC inhibition coincided with increased chro-
mosome missegregation rates: whereas 33 nM nocodazole pro-
voked mitotic abnormalities in only 6% of control RPE1 cells, 83% of
nocodazole-exposed Mad2cKD RPE1 suffered from defective mito-
ses, compared with 31% in the absence of nocodazole (Fig 5H).
Finally, when we combined SKI606 with SAC alleviation in the CIN
cell line HT29, in which MT polymerization rates cannot further be
increased (Fig 5F [Ertych et al, 2014]), we found that SKI606-imposed
Src inhibition was no longer acting synergistically with SAC alle-
viation in reducing cell numbers (Fig S5D), further indicating that
altered MT dynamics is underlying the synergy observed between
SKI606 and SAC inhibition. We conclude that altering MT poly-
merization rates synergizes with SAC inhibition in blocking cell
proliferation, thus providing new therapeutic opportunities for
cancers in which either the SAC or MT dynamics are disturbed.
Discussion
CIN and the resulting aneuploidy are hallmark features of cancer
cells. As both features discriminate cancer cells from healthy cells,
they are promising therapeutic targets. In this study, we explored
whether cells exhibiting CIN or stable aneuploidy displayed se-
lective vulnerabilities to particular drugs. As CIN and aneuploidy
trigger a number of responses in cells, including, but not limited to
proteotoxic stress (Oromendia et al, 2012; Stingele et al, 2012), a
deregulated cellular metabolism (Williams et al, 2008; Tang et al,
2011), a DNA damage response (Zhang et al, 2015; MacKenzie et al,
2017), senescence (Andriani et al, 2016), and apoptosis (Ohashi et al,
2015), we selected a small library of Food and Drug Administration-
approved drugs or compounds in clinical trials targeting aneuploidy/
CIN-related responses.
imaging experiments. P-values are calculated using a Wilcox test. (F)MT plus end growth rate in mitosis with and without 0.5 μM compound #1407. Each dot represents
the average of 20 MT movements within a cell, 20 cells per condition. (G) IncuCyte-based growth curves of control and Mad2cKD RPE1 in the presence or absence of 33 nM
nocodazole at days 8–16. AUC is plotted relative to cell line controls, P-values are calculated using a Wilcoxon–Mann–Whitney test. Data for DMSO control curves are also
used in Fig 4G and H. (H) Frequency of mitotic abnormalities in RPE1 cells with or without 0.5 μM compound #1407 and/or 33 nM nocodazole. Data were obtained by time-
lapse microscopy imaging and include at least three biological replicates. P-values are calculated by chi-squared test. “n” referrers to the number of mitotic events per
condition. “#” refers to that the same data are also used in Fig 2E.
Src inhibitors cause CIN specifically in SAC-inhibited cells Schukken et al. https://doi.org/10.26508/lsa.201900499 vol 3 | no 2 | e201900499 8 of 15
Aneuploid cells are sensitive to compounds that hyperactivate
the cellular metabolism
When we screened for compounds that selectively prevent ex-
pansion of aneuploid cells, we found that ZLN005, a transcriptional
stimulator of PGC-1α, was significantly more toxic to double-
trisomic RPE1 Ts12 Ts5 cells (Stingele et al, 2012) than control
cells. PGC-1α is a master regulator of mitochondrial biogenesis and
energy metabolism and its activation is, thus, expected to increase
mitochondrial respiration. None of the other tested compounds
showed reproducible toxicity specific to aneuploid cells. Although
somewhat disappointing, it is important to note that we only tested
a limited number of compounds (95 in total) in this screen and that
large-scale future screens can still reveal new therapeutic vul-
nerabilities of aneuploid cells. Still, our findings in aneuploid cells
correspond well with an earlier study by Tang et al (2011), who
identified the energy stress-inducing drug AICAR as a compound
that selectively targets aneuploid cells. AICAR activates AMP-
activated protein kinase (AMPK) leading to hyperactivation of mi-
tochondrial respiration and, thus, exacerbating metabolic stress
(Tang et al, 2011). Interestingly, AMPK acts as an activator of PGC-1α
(Jeon, 2016; Tan et al, 2016), and therefore, activation of AMPK
through AICAR is expected to phenocopy PGC-1α activation through
ZLN005, which is what we find. Therefore, our findings form an
important independent confirmation of these earlier findings, and
although our findings need to be confirmed in aneuploid cell lines
with other karyotypes to rule out karyotype specific effects, they do
warrant further research on the molecular mechanism underlying
this sensitivity.
Notably, ZLN005 did not emerge as a compound selectively
targeting cells with an ongoing CIN phenotype (Mad2cKD RPE1 cells;
Fig S3K) although the CIN phenotype in these cells was shown to
lead to substantial aneuploidy (Fig 2G). Possibly, aneuploid cells
need to adapt to the aneuploid state before becoming sensitive to
drugs that exacerbate the cellular metabolisms (Mad2cKD RPE1 cells
were only exposed for up to 12 d to a CIN phenotype). Alternatively,
as ongoing CIN and aneuploidy trigger (partially) different re-
sponses in cells (Bakker et al, 2018 Preprint), they might also display
differential vulnerabilities.
Synthetic lethal interaction between inhibition of the SAC and Src
activity
In addition to screening for compounds that selectively prevent
accumulation of aneuploid cells, we also screened for compounds
that selectively target cells with a CIN phenotype. For the latter, we
engineered RPE1 cells in which we could alleviate the SAC in an
inducible fashion (Mad2cKD RPE1 cells). This screen identified SKI606,
a Src inhibitor as a compound that selectively impairs accumulation
of cells with an alleviated SAC. Importantly, we validated the phe-
notypewith another Src inhibitor and confirmed that the effect of the
inhibitors is caused by Src inhibition because genetic perturbation of
Src by shRNA with SAC inhibition yields the same phenotype as
inhibitor treatment with SAC inhibition. Of note, we only succeeded in
reducing Src protein levels by approximately twofold using shRNA
and failed to engineer Src knockout cell lines using CRISPR engi-
neering (data not shown), which suggests that cells critically rely on
some remaining Src kinase activity for their survival. Therefore, to
phenocopy the selective targeting of CIN cells in vivo in future
studies, it will be important to titrate drug concentrations well.
We find that Src inhibition increases the chromosome mis-
segregation rate specifically in cells with an impaired mitotic
checkpoint. Although Src, to our knowledge, has not been directly
implicated with maintaining mitotic fidelity, it has been shown to
promote MT nucleation and regrowth (Colello et al, 2010) by binding
to γ–tubulin complexes (Kukharskyy et al, 2004). In addition, Src was
found to facilitate spindle orientation (Nakayama et al, 2012), and
oncogenic v-Src has been associated with cytokinesis failure
(Nakayama et al, 2017). This study revealed that Src inhibition re-
sults in increased MT polymerization rates, thus exacerbating the
CIN phenotype imposed by Mad2 loss. Interestingly, although
several Src inhibitors were found to affect tubulin polymerization,
this was typically labeled as “dualmechanism of action” rather than
a downstream effect of Src inhibition (Liu et al, 2013; Smolinski et al,
2018). Our study suggests that increased MT polymerization rates
are a direct consequence of Src inhibition and that, therefore, these
effects should be taken into consideration when treating patients
with Src inhibitors.
Mechanism underlying synthetic lethal interaction between SAC
alleviation and Src inhibition
What can explain the synergy between SAC alleviation and Src
inhibition in killing cells? Our data indicate that Src inhibition leads
to increased MT polymerization rates. Importantly, we show that
other MT-destabilizing drugs display the same lethal interaction
with SAC inhibition, further supporting our hypothesis that the
synthetic lethal interaction between SAC and Src inhibition is
explained by the role that Src has in regulating MT polymerization
rates. But why are SAC-deficient cells specifically vulnerable to
deregulatedMTdynamics andwhydoes Src inhibition not even impose
a modest CIN phenotype upon control RPE1 cells? When MT po-
lymerization rates are increased in cells with a fully functional SAC,
this will lead to decreased cell motility and increased kinetochore-
MT stability and, thus, hyper-stable kinetochore-MT interactions. In
this setting, the SAC will still delay mitosis until all chromosomal
abnormalities caused by Src inhibition are resolved. However,
when the SAC is also inhibited, it can no longer resolve the
hyperstable kinetochore–MT interactions caused by Src inhibition,
thus further increasing the frequency of chromosome missegregation
events (Fig 6).
Although we have shown in this study that Src inhibition de-
creases mitotic fidelity specifically in cells with an inhibited spindle
checkpoint, we have not further investigated the downstream
consequences of the resulting increased CIN rates. It is likely that
the growth defects we observed after combined Src and SAC in-
hibition are caused by a combination of cell cycle arrest and cell
death (for a recent review on this topic, see Chunduri & Storchova´
(2019)) and that whether cells arrest or undergo apoptosis depends
on the karyotypes that the aneuploid cells acquired after the CIN
insult. As the consequences of CIN can be highly tissue specific
(Foijer et al, 2013, 2017), it will be important to further investigate the
downstream consequences of altering MT dynamics in combination
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with spindle checkpoint inhibition in cell and organoid cultures and
in animal models before translating these findings to the clinic.
Implications for cancer therapy
CIN and aneuploidy are hallmarks of cancer cells, affecting ~70% of
all solid cancers (Duijf et al, 2013). Therefore, therapies that exploit
this feature might have a broad applicability. Our study suggests that
exacerbating CIN in cells with a preexisting CIN phenotype is a
powerful strategy to selectively target CIN cells. Indeed, that in-
creasing CIN is a powerful method to target genome instable cancers
has been reported by others as well (Kops et al, 2004; Thompson et al,
2010; Silk et al, 2013; Zasadil et al, 2016). One possible explanation for
this is that cancer cells tolerate low levels of CIN, until CIN rates
exceed a threshold, after which it becomes too toxic for cell survival.
Our results indicate that alteringMTdynamics to a level that does not
affect mitotic fidelity can already act synergistically with SAC defects
or inhibitors. This is particularly relevant for cancers in which either
the SAC or MT polymerization rates are affected to some extent, as a
defect in one process would render the cancer cells extremely
sensitive to the interference with the other process, making the
therapy much more specific to the cancers cells and thus reducing
side effects and long-term toxicity of the treatment.
Alternatively, the synthetic lethal interaction can be exploited to
target dividing cancer cells in combination therapy using both drugs
at much lower concentrations than when using the drugs as indi-
vidual agents. Indeed, others have also reported that SAC inhibitors
act synergistically with taxanes in killing cells in tissue culture (Janssen
et al, 2009; Jemaa` et al, 2013; J Tannous et al, 2013; Bargiela-Iparraguirre
et al, 2014; Maia et al, 2018) and in vivo in mouse studies (Jemaa` et al,
2013; Tannous et al, 2013; Maia et al, 2015, 2018;Wengner et al, 2016). The
observed synergy was shown to result from increased CIN (Thompson
& Compton, 2008; Janssen et al, 2009). In fact, three clinical trials
(NCT03328494, NCT02366949, and NCT03411161) combining Mps1
inhibitors with paclitaxel to target human cancers are currently
ongoing (Bayer, 2015; Boston-Pharmaceuticals, 2017; Servier, 2018). In
this study, we show that this synergy is not limited to Mps1 and
taxanes, and that alternative approaches to alter MT dynamics (such
as MT-destabilizing drugs such as vincristine or Src inhibitors) in
combination with SAC inhibition can be used to synergistically target
CIN cells by significantly increasing CIN. However, before our findings
can be taken into the clinic, further validation experiments are re-
quired, which should reveal whether Src inhibitors are as effective as
other MT polymerization deregulating drugs and whether such drugs
indeed act synergistically with SAC inhibitors in targeting cancer cells
in vivo.
Materials and Methods
Cell culture and compounds
RPE1 and MCF7 (American Type Culture Collection) cells were grown
in DMEM supplemented with 10% FBS and 100 units/ml penicillin and
100 μg/ml streptomycin. HT29 cells were growth in McCoy media
supplementedwith 10% FBS and Pen/Strep as above. Aneuploid cells
RPE1 with trisomy 12 and trisomy 5 (Ts12 Ts5) and RPE1 hTert cells
were kindly provided by the Storchova laboratory (Stingele et al,
2012). Most drugs used in this study were synthesized by Syncom B.V.,
except for AZD8055 (Sigma-Aldrich), EPZ015666 (Sigma-Aldrich) and
SKI-1 (Abcam). All drugs were dissolved in DMSO (Sigma-Aldrich) and
diluted in tissue culture medium as indicated. Used drug concen-
trations were titrated before the actual screen, starting from an initial
drug concentration of 10 μM. If the initial drug concentration of 10 μM
was (near-)toxic to wild-type RPE1 cells, the cells were next exposed
to 1 μM, 0.1 μM, 10 nM, or 1 nM of the compound, until a concentration
was found that was no longer toxic (see Supplemental Data 3 for all
initial drug titration growth curves).
Figure 6. Proposed mechanism of how increased MT
dynamics and SAC inhibition lead to synergistic
toxicity by exacerbating the CIN phenotype.
(A) Cells with normal tubulin dynamics and a functional
SAC have very low chromosome mis-segregation
rates. (B) Cells with normal tubulin dynamics but with
an alleviated SAC display intermediate chromosome
mis-segregation. (C) Cells with high tubulin dynamics,
but a functioning SAC correct unattached kinetochores
before entering anaphase. (D) Cells with increased MT
dynamics and an alleviated SAC suffer from
increased numbers of unaligned chromosomes that
are not signaled by the SAC leading to increased rates of
chromosome mis-segregation.
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Generation of Mad2cKD and SrccKD RPE1 cells
Mad2cKD RPE1 cells were generated by transducing RPE1 cells with a
lentiviral construct targeting human Mad2l1 (59-GGAAAGAATCAAGGAGG-
39) in a pTRIPZ backbone (Open Biosystems, Cat. no. RHS4696-
200677332). The cells were selected in 2 μg/ml puromycin for 48 h
and single-cell clones picked. Knockdown efficiency was deter-
mined for several clones by Western blot and the clone with the
largest Mad2 reduction was used for further experiments. SrccKD
RPE cells were generated by transducing lentiviral shRNA con-
structs into wild-type RPE1 cells. For this purpose, Src shRNA
constructs were engineered into a doxycycline-inducible pLKO
backbone that also contains the Tet operator sequence to allow for
conditional activation of the shRNA (Wiederschain et al, 2009). In
this vector, we replaced the puromycin resistance gene for a
blasticidin resistance gene. In the resulting Tet-pLKO-Blas vector,
we cloned the following Src-targeting shRNA sequences using









Cells were harvested during the logarithmic growth phase and lysed in
Egg Lysis Buffer (150 mM NaCl, 50 mM Hepes, pH 7.5, 5 mM EDTA, and
0.1%NP-40). Protein quantification was performed using Quick Start
Bradford assay, the Quick Start BSA standard kit (Bio-Rad Inc.), or
the MultiScan Go (Thermo Fisher Scientific). Antibodies used were
Actin (#4970; Cell Signaling Technologies), Tubulin (#ab7291; Abcam),
Src (#2109; Cell Signaling Technologies), and Mad2 (#610678; BD
Bioscience). Secondary antibodies were Anti-Mouse IRDye 680RD
(ab216778; Abcam) and Anti-Rabbit IRDye 800CW (ab216773; Abcam).
Blots were visualized and quantified using the Odyssey imaging
system (Li-Cor).
Single-cell sequencing
For single-cell sequencing, the cells were harvested, nuclei iso-
lated, and stained with Hoechst using nuclear isolation buffer.
Single nuclei were then sorted into 96-well plates using a FACSJazz
sorter (BD Bioscience). Single-cell DNA libraries were prepared and
sequenced (NextSeq 500; Illumina) with ~1% genomic DNA coverage
as described previously (van den Bos et al, 2016). Sequence Binary
Alignment maps files were analyzed with AneuFinder version 1.10.2
using the eDivisive analysis model at 1 MB as described elsewhere
(Bakker et al, 2016). Sequence Binary Alignment maps files and R
script used for analysis are available upon request. Single-cell
sequencing data have been deposited at the European Nucleo-
tide Archive under accession number PRJEB33217.
Metaphase spreads
Cells were cultured with 100 ng/ml Colcemid for 3 h, harvested,
incubated in 75 mM KCl for 15 min and fixated in 3:1 methanol: acetic
acid. Fixated cells were dropped on glass slides and nuclei visu-
alized using DAPI staining. Metaphase figures were inspected on an
Olympus BX43 microscope using a 63× lens. A minimum of 50
karyotyping spreads were counted per condition.
IncuCyte growth curves
For aneuploid drug screens, 200 RPE1 cells were sorted into each well
of 96-well plates by flow cytometry (FACSJazz; BD Bioscience). For the
CIN screen and follow-up screens, 1,600 cells were seeded per well in
a 96-well plate. For the latter, RPE1 Mad2cKD cells were treated with
1 μg/ml doxycycline for a minimum of 3 d before the start of any screen
and sorted into wells with 1 μg/ml doxycycline. Each well contained
media with drugs at the concentrations listed, and all measurements
were performed with technical triplicates for each plate. Cell growth
was monitored every 2 h using an IncuCyte Zoom live-cell anal-
ysis system (Essen BioScience Ltd.). Drug-containing media were
refreshed every 4 d, and for the CIN screen, the cells were passaged 1:
8 on day 4. Cell density was quantified using IncuCyte ZOOM 2018A
software. Cell confluency of control and CIN cells with drugs were
normalized to DMSO-treated cells (RPE1 + DMSO and Mad2cKD RPE
cells + DMSO, respectively) and calculated using two different ap-
proaches: AUC and slope analysis. As for the screens, multiple drugs
were tested per plate, the same DMSO control was used (at least one
per plate) to compare the effects of the drug-treated cells. The figure
legends indicate in which panels the same DMSO control was used.
AUC IncuCyte gowth curves
The AUC was estimated by taking the sum of the confluences per
time-point. These values were then set relative to each individual
cell line control AUC. For this, each AUC value was divided by the
mean cell line control AUC, that is, RPE1 control, RPE1 double tri-
somy (Ts12 Ts5), and RPE1 Mad2cKD cells were all analyzed as dif-
ferent cell lines so that the relative effect of each perturbation
could be compared per cell type. These relative AUC values were
then compared between cell lines per drug using a two-sided t test.
P-values in the screen were corrected for multiple testing using
Bonferroni correction (Haynes, 2013).
Slope analysis
An existing R script to analyze IncuCyte data (Chapman et al, 2016)
was modified to find the cutoff point for logarithmic growth. The
logarithmic growth cutoff was determined for each drug and cell
line combination, and the confluency at the cutoff was taken and
divided by the average confluency of the cell line control. Because
the slope is defined as the height (confluency) divided by width
(time at cutoff), and the cutoff time-point was set to be the same for
all DMSO and drug pairs, the cutoff time-points cancel out when
setting slope relative to the cell line control. The resulting relative
slope values were compared between cell lines per drug type using
a t test. The modified IncucyteDRC R package for screen slope
analysis is available upon request.
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Bliss independence test for synergistic toxicity between drugs
To validate that the observed effects in the compound screens were
synergistic and not only additive, we made use of the Bliss inde-
pendence test. For this, we calculated the fractional growth inhi-
bition, defined as 1-(AUCdrug-treated cells/AUCcontrol cells). Next, we
calculated the expected inhibitions, assuming drugs and CIN/
aneuploid conditions were additive, using the Bliss indepen-
dence equation: expected inhibition = Fa + Fb − (Fa*Fb), where Fa is
fractional growth inhibition of drug A and Fb was the fractional
growth inhibition of either CIN or aneuploid cell conditions. The
expected inhibition was compared with the actual growth inhibi-
tion; the P-value was determined using a t test, and the greater-
than-additive toxicity was found by taking the difference between
expected and actual fractional inhibition.
Growth curves analyzed by FIJI PHANTAST
For validation experiments, growth curves were determined from
daily microscope images using an Olympus IX51 microscope. For
these experiments, 5,300 cells were seeded per well of a 24-well
plate. Each well was imaged once a day for aminimumof 7 d. The FIJI
package PHANTAST (Jaccard et al, 2014) was used to estimate
confluency per well per time-point. PHANTAST settings were ε = 5
and σ ranging between 0.01 and 0.03 depending on cell coverage
and confluency accuracy. All measurements include at least three
technical replicates and three biological replicates (i.e., a minimum
of nine measurements per time point). Growth was plotted using
Prism software (GraphPad). As multiple drugs were tested per plate,
the same DMSO control was used to compare the effects of the
drug-treated cells. The figure legends indicate in which panels the
same DMSO control was used. Growth kinetics were normalized
identical to IncuCyte measurements.
AUC PHANTAST growth curves
The AUC was calculated by taking the sum of the confluency at all
time-points per condition. This was set relative to cell line growth
by dividing each AUC value by the average AUC for the DMSO cell
line control for each plate. These values were compared between
cell lines per drug with a two-sided t test.
Slope analysis FIJI growth curves
Growth curves were plotted on a log scale and the logarithmic
growth cutoff point was estimated manually for each condition. To
calculate the slope, the negative log of the confluency at that time-
point was divided by the cutoff day: −log(confluencycutoff)/Tcutoff.
This was divided by the average slope of the cell line control to
compensate for cell line growth differences. The replicates of the
relative slope values were compared between cell lines per
condition.
Live cell imaging and CIN analysis
RPE1, Mad2cKD RPE1, MCF7, and HT29 cells expressing H2B-GFP were
treated as indicated and imaged on a DeltaVision microscope
(Applied Precision Ltd.). Interphase phenotypes were analyzed by
quantifying nuclear morphology. Mitotic abnormalities were manually
quantified from overnight live cell imaging movies. Measurements
include at least three biological replicates, and numbers of cells
quantified are indicated in the text. A chi-squared test was used to
test whether differences between conditions were significant. Mi-
totic time was analyzed by calculating the time-points between the
first sign of DNA condensation to the last point before anaphase,
and from the first anaphase time-point to the time-point at
complete DNA de-condensation from time-lapse imaging data.
Cell motility assay
To quantify cell motility, time-lapse movies were analyzed using FIJI
TrackMate (Tinevez et al, 2017). A minimum of 15 overnight imaging
movies were used per condition, including at least three biological
replicates. TrackMate input conditions were optimized for each cell
type. RPE1 nuclear diameter was set at 20 μM, whereas MCF7 nuclear
diameter was set at 15 μM. Track statistics per condition were
combined and Track speed was plotted in R ggPlot2 (Wickham,
2016). Differences were calculated with two-sided t tests.
MT movement analysis
MT plus end assembly rates were determined by tracking EB3-GFP
protein (vector kindly provided by Linda Wordeman) in live cell
microscopy experiments as in Ertych et al (2014). Average assembly
rates (micrometer per minute) were calculated based on data
retrieved for 20 individual MTs per cell that were randomly selected.
A total of 20 cells were analyzed from three independent experi-
ments. Significance was assessed using a two-sided, unpaired t test.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900499.
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